CDC Identifies Potential Culprit for Vaping Illnesses
HENDERSON, Nev. — EVIO Inc. (the “Company” or “EVIO”) (OTCQB:EVIO) in response to the Centers for Disease Control and Prevention (“CDC”) preliminary finding on Vape illnesses, EVIO Labs is now offering tests for Tocopherol Acetate in hemp and cannabis products used for smoking and vaping; Also known as Vitamin E Acetate, it is sometimes used as an additive and flow agent in cannabis and hemp vape pens.
Vitamin E Acetate is a safe dietary supplement, but it is not generally recognized as safe for vaporization or inhalation. The CDC recently identified Vitamin E Acetate as a chemical of concern among people with e-cigarette or vaping-product associated lung injury (EVALI). Even at low temperatures, vaporization of Vitamin E Acetate, or other lipids, e.g. vegetable oils, medium chain triglycerides, mineral oil, etc., is a potentially dangerous practice that can lead to a condition known as lipoid pneumonitis. As of November 13, 42 deaths in the US have been attributed to EVALI-related pneumonitis.
In response, EVIO Labs added Vitamin E Acetate analysis to its repertoire of testing services. The company provides Vitamin E Acetate testing of vape cartridges for its marijuana and hemp (CBD) producers, consumers, as well as public health organizations and governmental bodies seeking additional information. The Vitamin E Acetate test is offered to licensed Cannabis companies in Oregon and California, and to hemp derived CBD companies nationwide. EVIO Labs produces a certificate of analysis (“COA”) for each sample detailing the results for tested samples.
“Our main focus is providing quality analyses of cannabis and hemp products to protect consumer and public safety. This is the first time that consumption of an ingredient in cannabis and hemp products has been tied to a potentially fatal illness,” said William Waldrop, CEO of EVIO Labs. “It is important that consumers buy tested product from reputable, state-licensed retailers. When purchasing hemp derived CBD products, look for the packaging that contain QR or bar codes that link to the original COA documenting what testing has been completed.”
About EVIO Inc.
EVIO Labs is the leading provider of cannabis, hemp and CBD testing. EVIO Labs services clients in the United States and Canada at its licensed and accredited cannabis, CBD and hemp full-service testing laboratory operations, and provides clients with quality analytical, R&D, and consulting services to product the best, compliant products. EVIO provides assurance to consumers that the potency on the label is what is in the package – and the product is free of harmful contaminants.
For more information, visit www.eviolabs.com.
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120005333/en/